Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 5;11(7):316.
doi: 10.3390/pharmaceutics11070316.

Biological Obstacles for Identifying In Vitro- In Vivo Correlations of Orally Inhaled Formulations

Affiliations
Review

Biological Obstacles for Identifying In Vitro- In Vivo Correlations of Orally Inhaled Formulations

Eleonore Fröhlich. Pharmaceutics. .

Abstract

Oral inhalation of drugs is the classic therapy of obstructive lung diseases. In contrast to the oral route, the link between in vitro and in vivo findings is less well defined and predictive models and parameters for in vitro-in vivo correlations are missing. Frequently used in vitro models and problems in obtaining in vivo values to establish such models and to identify the action of formulations in vivo are discussed. It may be concluded that major obstacles to link in vitro parameters on in vivo action include lack of treatment adherence and incorrect use of inhalers by patients, variation in inhaler performance, changes by humidity, uncertainties about lung deposition, and difficulties to measure drug levels in epithelial lining fluid and tissue. Physiologically more relevant in vitro models, improvement in inhaler performance, and better techniques for in vivo measurements may help to better understand importance and interactions between individual in vitro parameters in pulmonary delivery.

Keywords: composition of epithelial lining fluid; inhalers; lung deposition; patient compliance; pharmaceutical aerosols; pulmonary drug delivery.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Overview of factors that influence relevant parameters for drug delivery to in the lung.

Similar articles

Cited by

References

    1. Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25:563–570. doi: 10.1016/j.tibtech.2007.09.005. - DOI - PubMed
    1. Silva A., Tavares M., Aguiar-Ricardo A. Sustainable strategies for nano-in-micro particle engineering for pulmonary delivery. J. Nanopart. Res. 2014;16:2602. doi: 10.1007/s11051-014-2602-0. - DOI
    1. Pulmonary Drug Delivery Market. [(accessed on 2 April 2019)]; Available online: https://www.gilberttechnologies.eu/our-business/
    1. D’Urzo A., Chapman K., Donohue J., Kardos P., Maleki-Yazdi R., Price D. Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Pulm. Ther. 2018;4:1–19. doi: 10.1007/s41030-019-0090-1. - DOI - PMC - PubMed
    1. Cardot J.M., Davit B.M. In Vitro-In Vivo correlations: Tricks and traps. Aaps J. 2012;14:491–499. doi: 10.1208/s12248-012-9359-0. - DOI - PMC - PubMed

LinkOut - more resources